Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: Tenecteplase versus alteplase before thrombectomy for ischemic stroke
Author: Campbell, B.
Mitchell, P.
Churilov, L.
Yassi, N.
Kleinig, T.
Dowling, R.
Yan, B.
Bush, S.
Dewey, H.
Thijs, V.
Scroop, R.
Simpson, M.
Brooks, M.
Asadi, H.
Wu, T.
Shah, D.
Wijeratne, T.
Ang, T.
Miteff, F.
Levi, C.
et al.
Citation: New England Journal of Medicine, 2018; 378(17):1573-1582
Publisher: Massachusetts Medical Society
Issue Date: 2018
ISSN: 0028-4793
Statement of
B.C.V. Campbell, P.J. Mitchell, L. Churilov, N. Yassi, T.J. Kleinig, R.J. Dowling ... et al. (for the EXTEND-IA TNK Investigators)
Abstract: BACKGROUND: Intravenous infusion of alteplase is used for thrombolysis before endovascular thrombectomy for ischemic stroke. Tenecteplase, which is more fibrin-specific and has longer activity than alteplase, is given as a bolus and may increase the incidence of vascular reperfusion. METHODS: We randomly assigned patients with ischemic stroke who had occlusion of the internal carotid, basilar, or middle cerebral artery and who were eligible to undergo thrombectomy to receive tenecteplase (at a dose of 0.25 mg per kilogram of body weight; maximum dose, 25 mg) or alteplase (at a dose of 0.9 mg per kilogram; maximum dose, 90 mg) within 4.5 hours after symptom onset. The primary outcome was reperfusion of greater than 50% of the involved ischemic territory or an absence of retrievable thrombus at the time of the initial angiographic assessment. Noninferiority of tenecteplase was tested, followed by superiority. Secondary outcomes included the modified Rankin scale score (on a scale from 0 [no neurologic deficit] to 6 [death]) at 90 days. Safety outcomes were death and symptomatic intracerebral hemorrhage. RESULTS: Of 202 patients enrolled, 101 were assigned to receive tenecteplase and 101 to receive alteplase. The primary outcome occurred in 22% of the patients treated with tenecteplase versus 10% of those treated with alteplase (incidence difference, 12 percentage points; 95% confidence interval [CI], 2 to 21; incidence ratio, 2.2; 95% CI, 1.1 to 4.4; P = 0.002 for noninferiority; P = 0.03 for superiority). Tenecteplase resulted in a better 90-day functional outcome than alteplase (median modified Rankin scale score, 2 vs. 3; common odds ratio, 1.7; 95% CI, 1.0 to 2.8; P = 0.04). Symptomatic intracerebral hemorrhage occurred in 1% of the patients in each group. CONCLUSIONS: Tenecteplase before thrombectomy was associated with a higher incidence of reperfusion and better functional outcome than alteplase among patients with ischemic stroke treated within 4.5 hours after symptom onset.
Keywords: EXTEND-IA TNK Investigators
Rights: © 2018, Massachusetts Medical Society
DOI: 10.1056/NEJMoa1716405
Appears in Collections:Aurora harvest 8
Medicine publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.